InvestorsHub Logo
Followers 5
Posts 2568
Boards Moderated 0
Alias Born 11/03/2019

Re: None

Thursday, 09/30/2021 12:10:25 PM

Thursday, September 30, 2021 12:10:25 PM

Post# of 3749
$ATRX The license agreement is the second between Adhera and the Melior family of companies. On July 29, 2021, Adhera announced a license agreement pursuant to which the Company licensed MLR-1019 (armesocarb) from Melior Pharma 2, for the initial purpose of developing a new therapeutic for Parkinson’s disease. The Company expects to provide additional updates on this initiative in the coming weeks.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ATRX News